ReShape Lifesciences, Inc. is a medical technology company focused on the development and commercialization of minimally invasive devices to treat obesity and metabolic diseases. The company’s product portfolio centers on intragastric balloon systems designed to help patients achieve significant weight loss through non-surgical means. By offering outpatient solutions, ReShape Lifesciences seeks to address the growing global obesity epidemic while reducing the risks and recovery times associated with more invasive bariatric surgeries.
The company’s flagship device, the ReShape Dual Balloon, features a dual-balloon system that is endoscopically placed in the stomach to occupy space and promote early satiety. This approach enables patients to adhere to calorie-restricted diets more comfortably and supports long-term behavioral adjustments. ReShape Lifesciences also provides comprehensive training programs for healthcare professionals to ensure safe and effective device implantation, as well as patient follow-up services aimed at maximizing clinical outcomes.
Founded in 2013 and headquartered in San Clemente, California, ReShape Lifesciences initially secured CE Mark approval in Europe before pursuing regulatory clearances in other regions. The company has established partnerships and distribution agreements across North America, Europe and select markets in Asia, leveraging a network of obesity specialists, endoscopists and bariatric surgeons. Through these collaborations, ReShape Lifesciences continues to expand its commercial footprint and support the adoption of its minimally invasive therapies worldwide.
Under the leadership of Chief Executive Officer Mark T. Malinowski and an experienced management team with backgrounds in medical devices, obesity research and clinical nutrition, ReShape Lifesciences is committed to advancing its pipeline of obesity management solutions. The company invests in ongoing clinical studies to demonstrate the safety, efficacy and cost-effectiveness of its products, while exploring next-generation technologies aimed at improving patient comfort and enhancing long-term weight maintenance.
AI Generated. May Contain Errors.
Free RSLSD Stock Alerts